CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Climb Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$9.73−0.09 (-0.92%)
Close on Oct 19, 2026
- Market cap
- $740.98M
- P/E (TTM)
- –
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
-$67.88MFY2025